Emerging therapies for pulmonary hypertension: Striving for efficacy and safety

Journal of the American College of Cardiology

Volumn 41, Issue 12, 2003, Pages 2126-2129

  Kao, Peter N ^a   Faul, John L ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BERAPROST; BONE MORPHOGENETIC PROTEIN 2; CALCIUM CHANNEL BLOCKING AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; G PROTEIN COUPLED RECEPTOR; PHOSPHODIESTERASE INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; PROTEIN KINASE; RAPAMYCIN; SEROTONIN 2B RECEPTOR; SILDENAFIL; SIMVASTATIN; THROMBOXANE; UNIPROST;

ARTERY INTIMA PROLIFERATION; AUTOSOMAL DOMINANT INHERITANCE; CENTRAL VENOUS CATHETER; DEATH; EXERCISE TOLERANCE; GENE MUTATION; HEART FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; SURVIVAL; VASCULAR SMOOTH MUSCLE;

EID: 0037972141     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(03)00468-6     Document Type: Editorial

References (45)

1. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997;336:111-7.
2. Fishman AP, Fishman MC, Freeman BA, et al. Mechanisms of proliferative and obliterarive vascular diseases. Insights from the pulmonary and systemic circulations. NHLBI Workshop summary. Am J Respir Crit Care Med 1998;158:670-4.
3. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
4. Yi ES, Kim H, Alan H, et al. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162:1577-86.
5. Rich S, Rubin L, Walker AM, Schneeweiss S, Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 2000;117:870-4.
6. Glanville AR, Burke CM, Theodore J, Robin ED. Primary pulmonary hypertension. Length of survival in patients referred for heart-lung transplantation. Chest 1987;91:675-81.
7. Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70-5.
8. Tuder RM, Cool CD, Geraci M-W, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925-32.
9. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333:214-21.
10. Mason NA, Springall DR, Burke M, et al. High expression of endothelial nitric oxide synthase in plexiform lesions of pulmonary hypertension. J Pathol 1998;185:313-8.
11. Berger RM, Geiger R, Hess J, Bogers AJ, Mooi WJ. Altered arterial expression patterns of inducible and endothelial nitric oxide synthase in pulmonary plexogenic arteriopathy caused by congenital heart disease. Am J Respir Crit Care Med 2001;163:1493-9.
12. Komai H, Naito Y, Aimi Y, Kimura H. Nitric oxide synthase expression in lungs of pulmonary hypertensive patients with heart disease. Cardiovasc Pathol 2001;10:29-32.
13. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
14. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
15. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9.
16. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2002;39:1496-502.
17. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
18. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900.
19. Rich S, Brundage BH. High-dose calcium channel-blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
20. Galie N, Manes A, Branzi A. Medical therapy of pulmonary hypertension. The prostacyclins. Clin Chest Med 2001;22:529-37.
21. Clapp LH, Finney P, Turcato S, Tran S, Rubin LJ, Tinker A. Differential effects of stable prostacyclin analogs on smooth muscle proliferation and cyclic AMP generation in human pulmonary artery. Am J Respir Cell Mol Biol 2002;26:194-201.
22. Barst RJ, Rubin LJ, McGoon MD, Caldwell EJ, Long WA, Levy PS. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409-15.
23. Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997;30:343-9.
24. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-8.
25. McLaughlin W, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002;106:1477-82.
26. Kuhn KP, Byrne DW, Arbogast PW, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167:580-6.
27. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:2119-25.
28. Bland JM, Altman DG. Measurement error and correlation coefficients. BMJ 1996;313:41-2.
29. Faul JL, Demers EA, Burke CM, Poulter LW. The reproducibility of repeat measures of airway inflammation in stable atopic asthma. Am J Respir Crit Care Med 1999;160:1457-61.
30. Chinn S. Statistics in respiratory medicine. 2. Repeatability and method comparison. Thorax 1991;46:454-6.
31. Deng Z, Morse JH, Slager SL, et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 2000;67:737-44.
32. Lane KB, Machado RD, Pauciulo MW, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-4.
33. Thomson JR, Machado RD, Pauciulo MW, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37:741-5.
34. Newman JH, Wheeler L, Lane KB, et al. Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred. N Engl J Med 2001;345:319-24.
35. Atkinson C, Stewart S, Upton PD, et al. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672-8.
36. Runo JR, Vnencak-Jones CL, Prince M, et al. Pulmonary venoocclusive disease caused by an inherited mutation in bone morphogenetic protein receptor II. Am J Respir Crit Care Med 2003;167:889-94.
37. Chu JW, Kao PN, Faul JL, Doyle RL. High prevalence of autoimmune thyroid disease in pulmonary arterial hypertension. Chest 2002;122:1668-73.
38. Tuder RM, Groves B, Badesch DB, Voelkel NF. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275-85.
39. Launay JM, Herve P, Peoc'h K, et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129-35.
40. Humbert M, Deng Z, Simonneau G, et al. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002;20:518-23.
41. Faul JL, Nishimura T, Berry GJ, Benson GV, Pearl RG, Kao PN. Triptolide attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2000;162:2252-8.
42. Nishimura T, Faul JL, Berry GJ, Veve I, Kao PN, Pearl RG. 40-O-(2-Hydroxyethyl)-rapamycin attenuates pulmonary arterial hypertension and neointimal formation in rats. Am J Respir Crit Care Med 2001;163:498-502.
43. Nishimura T, Faul JL, Berry GJ, et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002;166:1403-8.
44. Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med 2002;166:1308-9.
45. Newman JH, Lane KB. Hypertensive pulmonary vascular disease. Dawn of the age of prevention? Am J Respir Crit Care Med 2000;162:2020-1.